Abzena, the life sciences group providing services and technologies for the discovery, design, development and manufacture of biopharmaceutical products, has signed an agreement to access a major cell line depository. The agreement with an unnamed institution will allow Abzena access to cell lines representing multiple different species, tissue types and genetic disorders. This removes the lengthy process of negotiating individual cell line licenses for Abzena and its customers. The impact...